1-3 of 3
Bojena Bitman
Close
Sort by
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Jenny L Black-Shinn, MPH, PhD, Jamyia Clark, MPH, Bojena Bitman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4060.
https://doi.org/10.1182/blood.V130.Suppl_1.4060.4060
Published: 2017
Journal Articles

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies

John C. Byrd, MD, Roger Owen, MD, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Bojena Bitman, Nataliya Chernyukhin, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Liat Schwartz-Sagi, MD, Edwin Tucker, MD, Nathan H. Fowler, MD, Matthew J. Streetly, BMBS, PhD MRCP, FRCPath, Adrian Wiestner, MD, Simon Rule, MD, Michael Wang, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 4326.
https://doi.org/10.1182/blood.V130.Suppl_1.4326.4326
Published: 2017